<DOC>
	<DOCNO>NCT00002756</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining one chemotherapy drug give induction intensification may kill cancer cell . PURPOSE : This phase II trial study well induction intensification work treat infant newly diagnose acute lymphocytic leukemia .</brief_summary>
	<brief_title>Induction Intensification Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess feasibility intensification two course high-dose methotrexate follow one course cyclophosphamide/etoposide induction later consolidation infant newly diagnose acute lymphoblastic leukemia . - Determine event-free survival shorten , intensive therapy patient . - Compare event-free survival rate infant receive regimen whose leukemic blast translocation involve 11q23 gene MLL . Secondary - Correlate presence minimal residual disease completion induction , begin continuation , completion therapy patient outcome . - Investigate clinical prognostic feature may associate outcome infant , bone marrow blast content day 8 , white blood cell count , age . - Correlate biologic characteristic leukemia cell diagnosis ( protocol POG-9900 ) outcome patient treat regimen . - Characterize pattern gene expression associate host disease characteristic treatment response patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord participate center presence CNS disease ( yes v ) . Patients receive induction chemotherapy comprise vincristine IV day 1 , 8 , 15 ; oral prednisone three time day day 1-21 ; daunorubicin IV 30 minute day 1-2 ; cyclophosphamide IV 30 minute every 12 hour day 3-4 ; asparaginase intramuscularly ( IM ) day 4 , 6 , 8 , 10 , 12 , 15 , 17 , 19 . Patients also receive triple intrathecal therapy comprise methotrexate , hydrocortisone , cytarabine day 1 , 8 , 15 filgrastim ( G-CSF ) subcutaneously ( SC ) IV begin day 5 continue day 20 , regardless blood count . Patients receive induction intensification chemotherapy comprise high-dose methotrexate IV 24 hour ; triple intrathecal therapy per induction therapy day 22 29 ; leucovorin calcium IV every 6 hour 2 dos begin 42 hour start high-dose methotrexate orally every 6 hour 3 dos . Patients also receive etoposide IV 2 hour cyclophosphamide IV 30 minute day 36-40 . Patients receive G-CSF SC IV begin day 41 continue blood count recover . Patients achieve morphologic remission recovery blood count G-CSF 48 hour receive reinduction chemotherapy comprise regimen induction therapy exception asparaginase IM begin day 1 ( week 8 ) continue every Monday , Wednesday , Friday total 8 dos triple intrathecal therapy day 1 15 ( week 8 10 ) . Patients receive G-CSF SC IV begin day 5 continue blood count recover . After blood count recovery , patient receive consolidation chemotherapy comprise triple intrathecal therapy per induction therapy day 1 ( week 11 ) ; high-dose methotrexate IV 24 hour week 8 12 ; leucovorin calcium IV every 6 hour 2 dos begin 42 hour start high-dose methotrexate orally every 6 hour 3 dos . Patients also receive etoposide IV 2 hour follow cyclophosphamide IV 30 minute day 15-19 ( week 13 ) . Patients receive G-CSF SC IV begin day 20 continue blood count recover . On day 29-31 ( week 15 ) , patient receive high-dose cytarabine IV 3 hour every 12 hour 4 dos asparaginase IM 6 hour completion high-dose cytarabine . Patients receive G-CSF begin 24 hour completion asparaginase continue blood count recover . Patients achieve morphologic remission blood count recovery G-CSF 48 hour receive continuation therapy comprise vincristine IV day 1 ; oral prednisone three time day day 1-5 ; triple intrathecal therapy day 1 ( week 18 22 ) . Patients also receive methotrexate IM week oral mercaptopurine daily week 19-21 , 23 , 24 . On week 25 , patient receive etoposide IV 2 hour daily follow cyclophosphamide IV 30 minute daily day 1-5 G-CSF SC IV begin day 6 continue blood count recover . Patients receive additional course continuation therapy week 28-35 . On week 38-48 , patient receive another identical course continuation therapy exclusion etoposide cyclophosphamide combination regimen . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : Approximately 58-104 patient accrue study within 2.1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia ( ALL ) acute undifferentiated leukemia No infant less 36 week ' gestation CNS testicular disease permit No Bcell ALL acute myeloid leukemia Previously untreated except follow : Steroid treatment within 48 hour diagnosis allow physical examination differential CBC immediately prior begin steroid Concurrent registration protocol POG9900 ( ALL classification study ) require Patients register POG9407 eligible pharmacokinetic part study PATIENT CHARACTERISTICS : Age : Under 1 diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No uncontrolled infection Adequate major organ function PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics No concurrent chronic steroid treatment Radiotherapy : Not specify Surgery : Not specify Other : No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
</DOC>